Clostridium difficile antibodies: a patent evaluation (WO2013028810)

Bibliography

• Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012;28:1-9
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011;8:17-26
   PubMed Web of Science ®Google Scholar
• Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008;122:1266-70
   PubMed Web of Science ®Google Scholar
• Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009;33:S42-5
   Web of Science ®Google Scholar
• Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23:529-49
   PubMed Web of Science ®Google Scholar
• Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008;46:1489-92
   PubMed Web of Science ®Google Scholar
• Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 2012;20:21-9
   Google Scholar
• Ng J, Hirota SA, Gross O, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010;139:542-52
   PubMed Web of Science ®Google Scholar
• Mitchell TJ, Ketley JM, Haslam SC, et al. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut 1986;27:78-85
   PubMed Web of Science ®Google Scholar
• Lima AA, Lyerly DM, Wilkins TD, et al. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 1988;56:582-8
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;34:390-7
   Google Scholar
• Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009;458:1176-9
   PubMed Web of Science ®Google Scholar
• Savidge TC, Pan WH, Newman P, et al. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003;125:413-20
   PubMed Web of Science ®Google Scholar
• Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007;11:5-10
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Oamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-93
   PubMed Web of Science ®Google Scholar
• Aronsson B, Granstrom M, Mollby R, et al. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985;13:97-101
   PubMed Web of Science ®Google Scholar
• Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011;60:1070-9
   PubMed Web of Science ®Google Scholar
• Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011;56:19-26
   PubMed Web of Science ®Google Scholar
• Musgrave CR, Bookstaver PB, Sutton SS, et al. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011;15:e438-48
   PubMed Web of Science ®Google Scholar
• Pothoulakis C, LaMont JT. Microbes and microbial toxins: paradigms for microbial mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001;280:178-83
   PubMed Web of Science ®Google Scholar
• Von Eichel-Streiber C, Sauerborn M. Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases. Gene 1990;96:107-13
   PubMed Web of Science ®Google Scholar
• Castagliuolo I, LaMont JT, Qiu B, et al. A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterol 1996;111:433-8
   PubMed Web of Science ®Google Scholar
• Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006;74:6339-47
   PubMed Web of Science ®Google Scholar
• Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28:965-9
   PubMed Web of Science ®Google Scholar
• Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 2011;286:8961-76
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Hariharan M, Elia M, et al. Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs 2010;2:190-8
   PubMed Web of Science ®Google Scholar
• Steele J, Mukherjee J, Parry N, et al. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 2013;207:323-30
   PubMed Web of Science ®Google Scholar
• Alfa MJ, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:2706-14
   PubMed Web of Science ®Google Scholar
• al-Barrak A, Embil J, Dyck B, et al. An outbreak of toxin A negative, toxin B positive Clostridium difficile- associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep 1999;25:65-9
   PubMedGoogle Scholar
• Kuijper EJ, deWeerdt J, Kato H, et al. Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis 2001;20:528-34
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205
   PubMed Web of Science ®Google Scholar
• Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010;467:711-13
   PubMed Web of Science ®Google Scholar
• Savidge TC, Urvil P, Oezguen N, et al. Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med 2011;17:1136-41
   PubMed Web of Science ®Google Scholar
• Oezguen N, Power TD, Urvil P, et al. Clostridial toxins: sensing a target in a hostile gut environment. Gut Microbes 2012;3:35-41
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15
   PubMed Web of Science ®Google Scholar